Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Bought by Bard Associates Inc.

Bard Associates Inc. increased its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 5.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 312,399 shares of the medical instruments supplier’s stock after buying an additional 15,404 shares during the period. Bard Associates Inc.’s holdings in Harvard Bioscience were worth $840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. grew its holdings in shares of Harvard Bioscience by 193.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock worth $649,000 after purchasing an additional 150,218 shares during the period. BNP Paribas Financial Markets increased its position in shares of Harvard Bioscience by 38.7% during the first quarter. BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock valued at $322,000 after acquiring an additional 21,183 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Harvard Bioscience by 13.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock valued at $783,000 after acquiring an additional 31,505 shares during the period. Vanguard Group Inc. boosted its position in shares of Harvard Bioscience by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock worth $9,125,000 after purchasing an additional 49,576 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in Harvard Bioscience by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock valued at $2,124,000 after purchasing an additional 42,800 shares during the last quarter. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

Harvard Bioscience Price Performance

Shares of Harvard Bioscience stock opened at $2.29 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.94 and a current ratio of 2.06. The business has a 50-day moving average of $2.55 and a 200 day moving average of $2.91. Harvard Bioscience, Inc. has a 12 month low of $2.15 and a 12 month high of $5.56.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.